Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02333929 · ClinicalTrials.gov registry record
Validation of Rivaroxaban Assay for US Registration
A clinical trial of Patients Receiving Rivaroxaban Treatment, sponsored by Diagnostica Stago.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT02333929 is a study of Patients Receiving Rivaroxaban Treatment that has completed, run by Diagnostica Stago. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02333929, a study of Patients Receiving Rivaroxaban Treatment, has completed, sponsored by Diagnostica Stago.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to demonstrate the performances of the STA® - Rivaroxaban Calibrator and STA® - Rivaroxaban Control in combination with the STA® - Liquid Anti-Xa to determine the quantity of rivaroxaban in plasma samples by measurement of its direct anti-Xa activity.
Conditions Studied
Interventions
- DEVICE STA- Rivaroxaban Calibrator&Control
Study Locations (1)
Pennsylvania
- Lehigh Valley Health Nrwork - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02333929
The ClinicalTrials.gov registry entry for NCT02333929 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Diagnostica Stago, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Patients Receiving Rivaroxaban Treatment appearing as the primary indexed condition, and to 1 intervention - of which STA- Rivaroxaban Calibrator&Control is the first listed.
NCT02333929 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02333929 about?
NCT02333929 is a clinical study titled "Validation of Rivaroxaban Assay for US Registration". The objective of the study is to demonstrate the performances of the STA® - Rivaroxaban Calibrator and STA® - Rivaroxaban Control in combination with the STA® - Liquid Anti-Xa to determine the quantity of rivaroxaban in plasma samples by measurement of its direct anti-Xa activity.
What is the current status of trial NCT02333929?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2015-03. Estimated completion is 2016-12.
What conditions does trial NCT02333929 study?
This clinical trial studies the following conditions: Patients Receiving Rivaroxaban Treatment.
What interventions are being tested in trial NCT02333929?
The interventions under investigation include: STA- Rivaroxaban Calibrator&Control (DEVICE).
Who is sponsoring clinical trial NCT02333929?
This trial is sponsored by Diagnostica Stago, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02333929 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.